14-Day prulifloxacin treatment of acute uncomplicated cystitis in women with recurrent urinary tract infections: A prospective, open-label, pilot trial with 6-month follow-up

Journal of Chemotherapy

Volumn 21, Issue 5, 2009, Pages 535-541

  Cai, Tommaso ^a   Mazzoli, S ^b   Nesi, G ^a   Boddi, V ^a   Mondaini, N ^a   Bartoletti, R ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Acute uncomplicated cystitis; Fluoroquinolone; Prulifloxacin; Recurrent urinary tract infections; Uropathogens

Indexed keywords

PRULIFLOXACIN; 1,3 DIOXOLANE DERIVATIVE; ANTIINFECTIVE AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; FEMALE; FOLLOW UP; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PILOT STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; URINALYSIS; URINARY FREQUENCY; URINARY TRACT INFECTION; URINARY URGENCY; URINE CULTURE; VAGINA FLORA; ACUTE DISEASE; ADOLESCENT; BACTERIUM; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; URINE; VAGINA;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIA; CYSTITIS; DIOXOLANES; FEMALE; FLUOROQUINOLONES; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PILOT PROJECTS; PIPERAZINES; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECURRENCE; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE; VAGINA; YOUNG ADULT;

EID: 75549088624     PISSN: 1120009X     EISSN: 19739478     Source Type: Journal    
DOI: 10.1179/joc.2009.21.5.535     Document Type: Article

References (32)

1. Hooton TM, Scholes D, Hughers JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335 (7): 468-474.
2. Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother 2000; 46 (Suppl 1): 1-7; discussion 63-65.
3. Grabe M, Bishop MC, Bjerklund-Johansen TE, Botto M, Cek M, Lobel B, Naber KG, Palou J. Tenke P. Guidelines on the Management of Urinary and Male Genital Tract Infections. http://www.uroweb.org/nc/professional-resources/guidelines/ online/
4. Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005; 3: 45.
5. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29 (4): 745-758.
6. Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004; 79 (8): 1048-1053.
7. Schaeffer AJ. The expanding role of fluoroquinolones. Dis Mon 2003; 49 (2): 129-147.
8. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-2234; discussion 2235-2236.
9. Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006; 19 (Suppl 1): 20-29.
10. Prats G, Rossi V, Salvatori E, Mirelis B. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther 2006; 4 (1): 27-41.
11. Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl 1): S216-227.
12. Ludwig M, Hoyme U, Weidner W. Recurrent urinary tract infection in women. Long-term antibiotic prophylaxis. Urologe A 2006; 45 (4): 436-442.
13. Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167 (20): 2207-2212.
14. Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncomplicated urinary tract infection in women. Cochrane Database Syst Rev 2005; (2): CD004682.
15. Motrich RD, Cuffini C, Mackern Oberti JP, Maccioni M, Rivero VE. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. J Infect 2006: 53 (3): 175-183.
16. Mazzoli S, Cai T, Rupealta V, Gavazzi A, Castricchi Pagliai R, Mondaini N, et al. Interleukin 8 and anti-chlamydia trachomatis mucosal IgA as urogenital immunologic markers in patients with C. trachomatis prostatic infection. Eur Urol 2007; 51 (5) 1385-1393.
17. Pannekoek Y, Westenberg SM, de Vries J. PCR assessment of Chlamydia trachomatis infection of semen specimens processed for artificial insemination. J Clin Microbiol 2000; 38 (10): 3763-3767.
18. Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293 (8): 949-955.
19. Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res 1976; 11 (4): 478-507.
20. Clayson D, Wild D, Doll H, Keating K, Gondek K. Validation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire. BJU Int 2005; 96 (3): 350-359.
21. Taur Y, Smith MA: Adherence to the Infectious Diseases Society of America Guidelines in the treatment of uncomplicated urinary tract infections. Clin Infect Dis 2007;44 (6): 769-774.
22. Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, randomized, double-blind trial. J Chemother 2007; 19 (3): 304-308.
23. Matsumoto T. Urinary tract infections in the elderly. Curr Urol Rep 2001; 2 (4): 330-333.
24. Norinder BS, Norrby R, Palmagren AC, Hollenberg S, Eriksson U, Nord CE. Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. Antimicrob Agents Chemother 2006; 50 (4): 1598-1530.
25. Stapleton A. Novel approaches to prevention of urinary tract infections. Infect Dis Clin North Am 2003; 17 (2): 457-471.
26. Stapleton A, Stamm WE. Prevention of urinary tract infection. Infect Dis Clin North Am 1997; 11 (3): 719-733.
27. Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad spectrum quinolone agent. Future Microbiol. 2009;4:13-24.
28. Gorlero F, Lorenzi P, Rosignoli MT, Picollo R, Ruggieri A, Barattè S, et al. Penetration of prulifloxacin into gynaecological tissues after single and repeated oral administrations. Drugs R D 2007; 8 (6): 373-381.
29. Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007; 13 (5): 285-290.
30. Fadda G, Nicoletti G, Schito GC, Tempera G. Antimicrobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005; 17 (3): 251-257.
31. Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosignoli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 2005; 74 (4): 326-331.
32. Mazzoli S. Conventional bacteriology in prostatitis patients: microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch Ital Urol Androl. 2007;79(2):71-5.